Generic semaglutide in India, and other weight-loss news
Novo Nordisk is facing generics of its GLP-1 drug in India, Atrogi is testing a new weight loss approach, and there’s new data on Structure’s lead drug. Indian patent on semaglutide expires tomorrow Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes…
